KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Operating Leases (2019 - 2026)

TherapeuticsMD filings provide 8 years of Operating Leases readings, the most recent being $4.8 million for Q1 2026.

  • On a quarterly basis, Operating Leases fell 19.06% to $4.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.8 million, a 19.06% decrease, with the full-year FY2025 number at $5.1 million, down 28.61% from a year prior.
  • Operating Leases hit $4.8 million in Q1 2026 for TherapeuticsMD, down from $5.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $7.9 million in Q1 2022 to a low of $4.8 million in Q1 2026.
  • Median Operating Leases over the past 5 years was $6.7 million (2023), compared with a mean of $6.5 million.
  • Biggest five-year swings in Operating Leases: increased 9.84% in 2024 and later fell 28.61% in 2025.
  • TherapeuticsMD's Operating Leases stood at $7.4 million in 2022, then dropped by 11.36% to $6.5 million in 2023, then rose by 9.84% to $7.2 million in 2024, then fell by 28.61% to $5.1 million in 2025, then dropped by 5.82% to $4.8 million in 2026.
  • The last three reported values for Operating Leases were $4.8 million (Q1 2026), $5.1 million (Q4 2025), and $5.4 million (Q3 2025) per Business Quant data.